# A Phase 2 Trial Testing ZP1848 in Patients With SBS

> **NCT02690025** · PHASE2 · COMPLETED · sponsor: **Zealand Pharma** · enrollment: 18 (actual)

## Conditions studied

- Short Bowel Syndrome

## Interventions

- **DRUG:** ZP1848

## Key facts

- **NCT ID:** NCT02690025
- **Lead sponsor:** Zealand Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02690025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02690025, "A Phase 2 Trial Testing ZP1848 in Patients With SBS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02690025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*